Efficacy of adalimumab in nail psoriasis by history of psoriatic arthritis and overall safety from final, open-label 26 weeks of a phase 3, randomized, placebo-controlled trial

Elewski BE., Armstrong AW., Coates LC., Rubel D., Rashid J., Geng Z., Gu Y., Servin OR., Behrens F.

Type

Conference paper

Publication Date

10/2019

Volume

81

Pages

AB201 - AB201

Permalink